CHAPEL HILL, N.C.--(BUSINESS WIRE)--Feb. 21, 2008--POZEN Inc.
(NASDAQ: POZN), today announced that Dr. William R. Kelce, vice
president, preclinical and early clinical development, has been
appointed adjunct associate professor, Department of Pediatrics,
School of Medicine, University of North Carolina, Chapel Hill
effective February 1, 2008.
In addition, Dr. Kelce is chairman of the Board of Publications
for the journal Toxicological Sciences and on the editorial review
boards for the journals Environmental Health Perspectives, Toxicology
and Applied Pharmacology, and Birth Defects Research, Developmental
and Reproductive Toxicology. Dr. Kelce has been a Fellow of the
Academy of Toxicological Sciences since 2000.
POZEN is a pharmaceutical company committed to developing
therapeutic advancements for diseases with unmet medical needs where
it can improve efficacy, safety, and/or patient convenience. POZEN's
efforts are focused primarily on the development of pharmaceutical
products for the treatment of acute and chronic pain and other
pain-related conditions. POZEN has development and commercialization
alliances with GlaxoSmithKline for the proposed product candidate
Treximet(TM) which is currently under review by the United States Food
and Drug Administration for the acute treatment of migraine, and with
AstraZeneca for the proposed product candidate PN 400 for conditions
such as osteoarthritis and rheumatoid arthritis in patients who are at
risk for developing NSAID-associated gastric ulcers. The company's
common stock is traded on The Nasdaq Stock Market under the symbol
"POZN". For detailed company information, including copies of this and
other press releases, see POZEN's website: www.pozen.com.
CONTACT: POZEN Inc.
Bill Hodges, Chief Financial Officer
Fran Barsky, Director, Investor Relations
SOURCE: POZEN Inc.